Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Telomerase reverse transcriptase (TERT) promotes immortalization by protecting telomeres in cancer cells. Mutation of the TERT promoter is one of the most common genetic alterations in
hepatocellular carcinoma
(
HCC
), indicating that TERT upregulation is a critical event in hepatocarcinogenesis. Regulators of TERT transcription are, therefore, predicted to be plausible targets for
HCC
treatment. We undertook a genome-wide shRNA library screen and identified C15orf55 and
C7orf43
as regulators of TERT expression in HepG2 cells. Promoter assays showed that C15orf55- and
C7orf43
-responsive sites exist between base pairs -58 and +36 and -169 and -59 in the TERT promoter, respectively. C15orf55 upregulates TERT expression by binding to two GC motifs in the SP1 binding site of the TERT promoter.
C7orf43
upregulates TERT expression through Yes-associated protein 1. The expression levels of C15orf55 and
C7orf43
also correlated with that of TERT, and were significantly increased in both
HCC
tissues and their adjacent non-tumor tissues, compared to normal liver tissues from non-
HCC
patients. Analysis of 377
HCC
patients in The Cancer Genome Atlas dataset showed that overall survival of patients with low levels of C15orf55 and
C7orf43
expression in tumor tissues was better compared with patients with high levels of C15orf55 and/or high
C7orf43
expression. These results indicate that C15orf55 and
C7orf43
are involved in the incidence and progression of
HCC
by upregulating TERT. In conclusion, we identified C15orf55 and
C7orf43
as positive regulators of TERT expression in
HCC
tissues. These genes are promising targets for
HCC
treatment.
...
PMID:Identification of genes involved in the regulation of TERT in hepatocellular carcinoma. 3044 97